980 related articles for article (PubMed ID: 24534255)
1. PPAR agonists reduce steatosis in oleic acid-overloaded HepaRG cells.
Rogue A; Anthérieu S; Vluggens A; Umbdenstock T; Claude N; de la Moureyre-Spire C; Weaver RJ; Guillouzo A
Toxicol Appl Pharmacol; 2014 Apr; 276(1):73-81. PubMed ID: 24534255
[TBL] [Abstract][Full Text] [Related]
2. Farnesol induces fatty acid oxidation and decreases triglyceride accumulation in steatotic HepaRG cells.
Pant A; Rondini EA; Kocarek TA
Toxicol Appl Pharmacol; 2019 Feb; 365():61-70. PubMed ID: 30611723
[TBL] [Abstract][Full Text] [Related]
3. Monascin and ankaflavin act as natural AMPK activators with PPARα agonist activity to down-regulate nonalcoholic steatohepatitis in high-fat diet-fed C57BL/6 mice.
Hsu WH; Chen TH; Lee BH; Hsu YW; Pan TM
Food Chem Toxicol; 2014 Feb; 64():94-103. PubMed ID: 24275089
[TBL] [Abstract][Full Text] [Related]
4. The effects of herbal composition Gambigyeongsinhwan (4) on hepatic steatosis and inflammation in Otsuka Long-Evans Tokushima fatty rats and HepG2 cells.
Yoon S; Kim J; Lee H; Lee H; Lim J; Yang H; Shin SS; Yoon M
J Ethnopharmacol; 2017 Jan; 195():204-213. PubMed ID: 27845265
[TBL] [Abstract][Full Text] [Related]
5. PPARα/γ agonists and antagonists differently affect hepatic lipid metabolism, oxidative stress and inflammatory cytokine production in steatohepatitic rats.
Zhang Y; Cui Y; Wang XL; Shang X; Qi ZG; Xue J; Zhao X; Deng M; Xie ML
Cytokine; 2015 Sep; 75(1):127-35. PubMed ID: 26194065
[TBL] [Abstract][Full Text] [Related]
6. Transcriptional regulation of human and rat hepatic lipid metabolism by the grapefruit flavonoid naringenin: role of PPARalpha, PPARgamma and LXRalpha.
Goldwasser J; Cohen PY; Yang E; Balaguer P; Yarmush ML; Nahmias Y
PLoS One; 2010 Aug; 5(8):e12399. PubMed ID: 20811644
[TBL] [Abstract][Full Text] [Related]
7. Induction of vesicular steatosis by amiodarone and tetracycline is associated with up-regulation of lipogenic genes in HepaRG cells.
Anthérieu S; Rogue A; Fromenty B; Guillouzo A; Robin MA
Hepatology; 2011 Jun; 53(6):1895-905. PubMed ID: 21391224
[TBL] [Abstract][Full Text] [Related]
8. Roles of PPARs in NAFLD: potential therapeutic targets.
Tailleux A; Wouters K; Staels B
Biochim Biophys Acta; 2012 May; 1821(5):809-18. PubMed ID: 22056763
[TBL] [Abstract][Full Text] [Related]
9. Oxymatrine attenuates hepatic steatosis in non-alcoholic fatty liver disease rats fed with high fructose diet through inhibition of sterol regulatory element binding transcription factor 1 (Srebf1) and activation of peroxisome proliferator activated receptor alpha (Pparα).
Shi LJ; Shi L; Song GY; Zhang HF; Hu ZJ; Wang C; Zhang DH
Eur J Pharmacol; 2013 Aug; 714(1-3):89-95. PubMed ID: 23791610
[TBL] [Abstract][Full Text] [Related]
10. PPAR agonists treatment is effective in a nonalcoholic fatty liver disease animal model by modulating fatty-acid metabolic enzymes.
Seo YS; Kim JH; Jo NY; Choi KM; Baik SH; Park JJ; Kim JS; Byun KS; Bak YT; Lee CH; Kim A; Yeon JE
J Gastroenterol Hepatol; 2008 Jan; 23(1):102-9. PubMed ID: 18171348
[TBL] [Abstract][Full Text] [Related]
11. Puerarin ameliorates hepatic steatosis by activating the PPARα and AMPK signaling pathways in hepatocytes.
Kang OH; Kim SB; Mun SH; Seo YS; Hwang HC; Lee YM; Lee HS; Kang DG; Kwon DY
Int J Mol Med; 2015 Mar; 35(3):803-9. PubMed ID: 25605057
[TBL] [Abstract][Full Text] [Related]
12. Evaluating the effect of a mixture of two main conjugated linoleic acid isomers on hepatic steatosis in HepG2 cellular model.
Jalilian A; Golmohammadi T; Meshkani R; Koushki M; Eivazi N; Khorzoughi RB; Fard SRH; Paknejad M
Mol Biol Rep; 2021 Feb; 48(2):1359-1370. PubMed ID: 33580458
[TBL] [Abstract][Full Text] [Related]
13. Differential effects of selective- and pan-PPAR agonists on experimental steatohepatitis and hepatic macrophages
Lefere S; Puengel T; Hundertmark J; Penners C; Frank AK; Guillot A; de Muynck K; Heymann F; Adarbes V; Defrêne E; Estivalet C; Geerts A; Devisscher L; Wettstein G; Tacke F
J Hepatol; 2020 Oct; 73(4):757-770. PubMed ID: 32360434
[TBL] [Abstract][Full Text] [Related]
14. Compound K modulates fatty acid-induced lipid droplet formation and expression of proteins involved in lipid metabolism in hepatocytes.
Kim MS; Lee KT; Iseli TJ; Hoy AJ; George J; Grewal T; Roufogalis BD
Liver Int; 2013 Nov; 33(10):1583-93. PubMed ID: 23998390
[TBL] [Abstract][Full Text] [Related]
15. Enhanced expression of pro-inflammatory mediators and liver X-receptor-regulated lipogenic genes in non-alcoholic fatty liver disease and hepatitis C.
Lima-Cabello E; García-Mediavilla MV; Miquilena-Colina ME; Vargas-Castrillón J; Lozano-Rodríguez T; Fernández-Bermejo M; Olcoz JL; González-Gallego J; García-Monzón C; Sánchez-Campos S
Clin Sci (Lond); 2011 Mar; 120(6):239-50. PubMed ID: 20929443
[TBL] [Abstract][Full Text] [Related]
16. Regulation of Drug Metabolism by the Interplay of Inflammatory Signaling, Steatosis, and Xeno-Sensing Receptors in HepaRG Cells.
Tanner N; Kubik L; Luckert C; Thomas M; Hofmann U; Zanger UM; Böhmert L; Lampen A; Braeuning A
Drug Metab Dispos; 2018 Apr; 46(4):326-335. PubMed ID: 29330220
[TBL] [Abstract][Full Text] [Related]
17. Peroxisome proliferator-activated receptor-α agonist, Wy 14,643, improves metabolic indices, steatosis and ballooning in diabetic mice with non-alcoholic steatohepatitis.
Larter CZ; Yeh MM; Van Rooyen DM; Brooling J; Ghatora K; Farrell GC
J Gastroenterol Hepatol; 2012 Feb; 27(2):341-50. PubMed ID: 21929649
[TBL] [Abstract][Full Text] [Related]
18. A systems biology approach to the hepatic role of the oxysterol receptor LXR in the regulation of lipogenesis highlights a cross-talk with PPARα.
Ducheix S; Podechard N; Lasserre F; Polizzi A; Pommier A; Murzilli S; Di Lisio C; D'Amore S; Bertrand-Michel J; Montagner A; Pineau T; Loiseau N; Lobaccaro JM; Martin PG; Guillou H
Biochimie; 2013 Mar; 95(3):556-67. PubMed ID: 23063693
[TBL] [Abstract][Full Text] [Related]
19. Effects of combined PPAR-γ and PPAR-α agonist therapy on fructose induced NASH in rats: Modulation of gene expression.
Abd El-Haleim EA; Bahgat AK; Saleh S
Eur J Pharmacol; 2016 Feb; 773():59-70. PubMed ID: 26825546
[TBL] [Abstract][Full Text] [Related]
20. Acanthoic acid modulates lipogenesis in nonalcoholic fatty liver disease via FXR/LXRs-dependent manner.
Han X; Cui ZY; Song J; Piao HQ; Lian LH; Hou LS; Wang G; Zheng S; Dong XX; Nan JX; Wu YL
Chem Biol Interact; 2019 Sep; 311():108794. PubMed ID: 31421115
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
